Whoop closed a $575 million Series G last week. Series G. You’re either on a clear IPO path at that stage, or stuck in a capital cycle that never quite ends.
OpenEvidence raised in Q1 as well. So did several others. Every one of these deals carries an AI-on-clinical-workflows story — investors aren’t writing checks for digital health broadly anymore, they’re writing checks for anything with a machine learning layer on top of care delivery or diagnostics.
It’s the 2021 playbook with an AI upgrade. At least two late-stage Q1 raises are confirmed, with reporting suggesting more closed in the same window. Late-stage capital concentrating in large rounds while earlier-stage deals get squeezed. Some of that 2021 vintage hasn’t aged well. Those companies aren’t leading this cycle.
The buyer rationale across all these deals is the same: AI reduces physician burden, improves throughput, gives payers a data story. The pitch hasn’t changed quarter to quarter. What’s changed is the check size. Whether those economics justify Whoop’s $575M depends on the post-money valuation, which the company hasn’t disclosed.
That number surfaces when Whoop decides to release it. At Series G, the only follow-on document that investors are waiting for is an S-1.
Diana Kowalski